Panel Disdussion

3rd International Congress of of Nuclear Medicine & & 15th 15th Iranian Annual Annual Congress of
Congress of Nuclear Medicine
Shahid Beheshti Shahid Beheshti University University of Medical of Medical Sciences Sciences 19-21 19-21 May May 2011
In vivo tracking of 111In-Oxine Labeled Mesenchymal Stem
Cells Following Infusion in Patients with Advanced Cirrhosis
Sahar Mirpour 1 , Ali Gholamrezanezhad 1 , Mohammad Bagheri 2 , Mehdi
Mohamadnejad 2 , Kamran Alimoghadam 3 , Reza Malekzadeh 2 , Mohsen
Saghari 1 , Nader Ahmadin 1 , Maryam Bashtar 3
1 Tehran University of Medical Science, Research Institute for Nuclear Medicine
2 Tehran University of Medical Science, Digestive Diseases Research Center
3 Tehran University of Medical Science, Department of Hematology
Background: So far progress from the use of both in-vitro and invivo
regenerative medicine models already offers hope for the use of
stem-cells as powerful new therapeutic option for different human
diseases. We initiated a pilot study on human to evaluate stem-cell
bio-distribution after peripheral infusion of mesenchymal stem-cells
(MSCs) in patients with cirrhosis.
Methods: After three passages of MSCs, the first patient (F,62y/o)
received a total of 270x106cells and the second one(M,17y/o) was
infused with 290x106cells. In both patients only 50% of cells were
labeled with 111In-Oxine.A specific activity of 0.67MBq/106 cells and
0.71MBq/106 cells were maintained for the injected labeled cells of
the first and second patients, respectively. The labeling-efficiency
was 36.2% for the cells injected to the first patient and 38.8% for the
second patient. Planar whole body acquisitions(anterior/posterior
projections)were acquired immediately following infusion as well as at
2h,4h,6h,24h,48h, 7th and 10th days after stem-cell infusion. The
SPECT images were obtained at 24th hour post-infusion.
Results: Immediately after I.V. infusion, the radioactivity (labeled-
MSCs) was first observed to accumulate in the lungs, and gradually
shifted to the liver and spleen during the following hours to days. On
SPECT images of the 24th hour, the activity distribution was rather
homogenous throughout the livers and enlarged spleens. Region of
Interest(ROI)analysis in the first patient showed that the percentage
of the homing of the cells into the liver (following decay and
background correction and geometric mean calculation) to be 2.8%,
4.1%,4.1%,4.3%,4.7%,12% and13.5% at 2h,4h,6h,24h,48h,7th and
10th days. The respective values for the second patient were 0%,
3.6%, 3.6%, 3.9%, 4%, 11% and 13%. The residual
activities(labeled MSCs) in the spleen of first patient were
2%,3%,3%,4%,5%,21% and 30% in the previously-mentioned time
points and were 2.5%, 4%, 5%, 7%, 9%, 14% and 42%, for the
second one, respectively.
Conclusion: The infusion of stem cell throughout a peripheral vein is
a safe and feasible alternative route of administration for possible
regenerative treatment of patients with cirrhosis. Also, cell labeling
with 111In-Oxine is a suitable method for following-up of cell
distribution after infusion. Regarding the previous studies in noncirrhotic
patients, the bio-distribution of MSCs in patients with liver
cirrhosis is altered significantly (with decreased hepatic and almost
77